Back to Laryngeal Squamous Cell Carcinoma

Laryngeal Squamous Cell Carcinoma — Clinical Trials

MONDO:000559536 active·21 recruitingLast updated: Mar 19, 2026, 6:46 AM

Trial Landscape

Laryngeal Squamous Cell Carcinoma has an active clinical trial landscape, driven by procedure and drug treatment.

Recruiting

Active Trials

By Approach

Procedure32

Drug Treatment30

Biological Therapy19

Medical Device1

16 additional trials involve behavioral, dietary, diagnostic, or observational approaches.

By Phase

Early Phase 1

Phase 1

Phase 2

Phase 3

6 trials are observational or have no phase designation.

Sponsor Types

Academic/Other29NIH14Collaborative Network2Industry1

Top Sponsors

Rapa Therapeutics LLC

Trial Locations

United States35 trials

Germany4 trials

Canada3 trials

Netherlands2 trials

Brazil1 trial

Hong Kong1 trial

Puerto Rico1 trial

South Africa1 trial

Italy1 trial

Trials often recruit across multiple countries, so totals exceed the trial count.

46 Trials

Phase 3Recruiting

NCT06589804

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Mar 2025Est. completion: Nov 2029Updated: Mar 2026

Phase 3Recruiting

NCT05333523

Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.

Sponsor:Radboud University Medical Center

NetherlandsStarted: Dec 2023Est. completion: Dec 2029Updated: Nov 2025

Phase 2Recruiting

NCT06980038

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Aug 2026Est. completion: Nov 2027Updated: Mar 2026

Phase 2Recruiting

NCT07195734

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Oct 2026Est. completion: Feb 2033Updated: Mar 2026

Phase 2Recruiting

NCT05136196

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Dec 2022Est. completion: Jan 2027Updated: Mar 2026

Phase 2Recruiting

NCT01810913

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Mar 2013Est. completion: Jan 2027Updated: Mar 2026

Phase 2Recruiting

NCT06030440

De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Sponsor:University of Erlangen-Nürnberg Medical School

GermanyStarted: Jan 2024Est. completion: Sep 2033Updated: Mar 2026

Phase 2Recruiting

NCT02734537

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

Sponsor:ECOG-ACRIN Cancer Research Group

United StatesStarted: Nov 2016Est. completion: Dec 2027Updated: Mar 2026

Phase 2Recruiting

NCT07063212

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

Sponsor:Memorial Sloan Kettering Cancer Center

United StatesStarted: Jul 2025Est. completion: Jan 2028Updated: Feb 2026

Phase 2Recruiting

NCT06636734

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

Sponsor:Emory University

United StatesStarted: Dec 2024Est. completion: Dec 2028Updated: Feb 2026

Phase 3Active, Not Recruiting

NCT05721755

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

Sponsor:ECOG-ACRIN Cancer Research Group

United StatesStarted: Jun 2023Est. completion: Mar 2030Updated: Mar 2026

Phase 3Active, Not Recruiting

NCT00588770

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Aug 2008Est. completion: Feb 2026Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT05063552

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Mar 2023Est. completion: Dec 2027Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT05172258

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jul 2022Est. completion: Jun 2027Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT04030455

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

Sponsor:M.D. Anderson Cancer Center

United StatesStarted: Aug 2019Est. completion: Sep 2026Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT04862650

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Sponsor:Marcelo Bonomi

United StatesStarted: Nov 2021Est. completion: Dec 2026Updated: Feb 2026

Phase 2Active, Not Recruiting

NCT00494182

Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Sponsor:M.D. Anderson Cancer Center

United StatesStarted: Apr 2007Est. completion: Dec 2026Updated: Dec 2025

Phase 1Active, Not Recruiting

NCT04533750

Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Dec 2021Est. completion: Dec 2026Updated: Mar 2026

Phase 1Active, Not Recruiting

NCT04576091

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jul 2022Est. completion: Dec 2025Updated: Dec 2024

Early Phase 1Active, Not Recruiting

NCT05245682

Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer

Sponsor:Emory University

United StatesStarted: Feb 2022Est. completion: Jul 2026Updated: Jan 2026

Stay informed about clinical trials for Laryngeal Squamous Cell Carcinoma.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 19, 2026 at 6:46 AM

Laryngeal Squamous Cell Carcinoma — Clinical Trials

Trial Landscape

By Approach

By Phase

Sponsor Types

Top Sponsors

Trial Locations

46 Trials

Open Trials26

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

Active Trials10

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer

Other10